-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The global new crown pneumonia epidemic is still continuing
.
According to statistics, the incidence of new coronary pneumonia in adolescents between the ages of 12 and 17 is about 900 per 100,000 population.
Although children with Covid-19 usually have milder symptoms than adults, it can also lead to hospitalization.
The new crown pneumonia children Recently researchers examined the safety, mRNA-1273 vaccine in 12-17-year-olds in the population of immune immunogenicity and efficacy
This study is a phase II-III clinical study.
Healthy 12-17-year-old adolescents received 2 doses of mRNA-1273 vaccine (100μg each time) or placebo, with an interval of 28 days
Prevent infection
A total of 3732 adolescents participated in the study, of which 2489 were vaccinated and 1243 received a placebo
.
In the vaccine group, the most common adverse events were pain at the injection site (93.
1% after the first vaccination, 92.
Adverse events in adolescents after mRNA-1273 vaccination
Adverse events in adolescents after mRNA-1273 vaccination Adverse events in adolescents after mRNA-1273 vaccinationCompared with young people, the geometric mean titer ratio of virus neutralizing antibody titers after vaccination in young people is 1.
08, and the absolute difference in serological response is 0.
2%, reaching non-inferiority
.
14 days after completing the second dose of vaccination, there were no cases of new coronary pneumonia infection in the vaccine group and 4 cases in the placebo group
.
Compared with young people, the geometric mean titer ratio of virus neutralizing antibody titers after vaccination in young people is 1.
Protective efficacy of mRNA-1273 vaccine
The protective effect of mRNA-1273 vaccine The protective effect of mRNA-1273 vaccineStudies believe that the mRNA-1273 vaccine is safe in adolescents aged 12-17, and its immune response induction effect is equivalent to that of adults, and it can effectively prevent new coronary pneumonia
.
The mRNA-1273 vaccine is safe in adolescents aged 12-17.
Original source:
Kashif Ali et al.
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
Leave a message here